Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Keystone

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
ACR Open Rheumatology|November 29, 2019
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 YearsJanet E Pope, Edward Keystone, Shahin Jamal, et al.
Clinical Reviews in Allergy & Immunology|December 10, 2009
Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosisPeter Lea, Edward Keystone, Sasi Mudumba, et al.
Arthritis Care & Research|April 27, 2018
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6Ronald F van Vollenhoven, Eun Bong Lee, Lara Fallon, et al.
Rheumatology (Oxford, England)|March 25, 2017
Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registryArthur Kavanaugh, Edward Keystone, Jeffrey D Greenberg, et al.
Arthritis Research & Therapy|November 19, 2010
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD studySudha Visvanathan, Mahboob U Rahman, Edward Keystone, et al.
Annals of the Rheumatic Diseases|May 5, 2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexateStanley B Cohen, Edward Keystone, Mark C Genovese, et al.
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studiesTabitha N Kung, Jessica Dennis, Yiqing Ma, et al.
British Journal of Clinical Pharmacology|April 6, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjectsAntonia Davidson, Darin Brimhall, Jonathan Kay, et al.
International Journal of Rheumatic Diseases|July 26, 2016
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesRoy Fleischmann, Joel Kremer, Yoshiya Tanaka, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
ACR Open Rheumatology|November 29, 2019
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 YearsJanet E Pope, Edward Keystone, Shahin Jamal, et al.
Clinical Reviews in Allergy & Immunology|December 10, 2009
Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosisPeter Lea, Edward Keystone, Sasi Mudumba, et al.
Arthritis Care & Research|April 27, 2018
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6Ronald F van Vollenhoven, Eun Bong Lee, Lara Fallon, et al.
Rheumatology (Oxford, England)|March 25, 2017
Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registryArthur Kavanaugh, Edward Keystone, Jeffrey D Greenberg, et al.
Arthritis Research & Therapy|November 19, 2010
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD studySudha Visvanathan, Mahboob U Rahman, Edward Keystone, et al.
Annals of the Rheumatic Diseases|May 5, 2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexateStanley B Cohen, Edward Keystone, Mark C Genovese, et al.
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studiesTabitha N Kung, Jessica Dennis, Yiqing Ma, et al.
British Journal of Clinical Pharmacology|April 6, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjectsAntonia Davidson, Darin Brimhall, Jonathan Kay, et al.
International Journal of Rheumatic Diseases|July 26, 2016
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesRoy Fleischmann, Joel Kremer, Yoshiya Tanaka, et al.
Pageof 9